Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.
Yi-Chou HouCai-Mei ZhengTzung-Hai YenKuo-Cheng LuPublished in: International journal of molecular sciences (2020)
The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre- and post- glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- insulin resistance
- newly diagnosed
- peritoneal dialysis
- type diabetes
- clinical trial
- adipose tissue
- heart failure
- glycemic control
- phase iii
- cardiovascular events
- cardiovascular disease
- patient reported outcomes
- high fat diet
- left ventricular
- risk factors
- blood glucose
- weight loss